Industry Overview
The Second-Generation Antipsychotics is at USD 4.5Billion in 2024 and is expected to reach 8.0Billion by 2032. The Second-Generation Antipsychotics is driven by increasing demand in end-use industries, technological advancements, research and development (R&D), economic growth, and global trade.Second-Generation Antipsychotics Market Size in (USD Billion) CAGR Growth Rate 8.00%
| Study Period | 2020-2032 |
| Market Size (2024): | 4.5Billion |
| Market Size (2032): | 8.0Billion |
| CAGR (2024 - 2032): | 8.00% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | North America |
www.www.htfmarketinsights.com
The Second-Generation Antipsychotics (SGAs) Market comprises medications such as risperidone, olanzapine, quetiapine, and aripiprazole, used primarily to treat schizophrenia, bipolar disorder, and other psychotic conditions. These drugs act on dopamine and serotonin receptors, offering improved efficacy and fewer extrapyramidal side effects compared to first-generation antipsychotics. The market is driven by rising mental health awareness, increasing prevalence of psychiatric disorders, and expanding indications. Major pharmaceutical companies include Johnson & Johnson, Lilly, and Otsuka. Challenges involve managing metabolic side effects like weight gain and diabetes. The industry is focused on developing novel formulations, long-acting injectables, and personalized therapies. Regulatory approval processes, patent expirations, and generic entries influence market dynamics. Overall, the market aims to improve patient compliance, reduce side effects, and enhance therapeutic outcomes for mental health disorders worldwide.
Competitive landscape
The key players in the Second-Generation Antipsychotics are intensifying their focus on research and development (R&D) activities to innovate and stay competitive. Major companies, such as Johnson & Johnson, Eli Lilly, Otsuka, AstraZeneca, Pfizer, GSK, Lundbeck, Sun Pharma, Teva, Novartis, Allergan, Merck, Biogen, Sanofi, Takeda, H. Lundbeck, Neurocrine, Vanda, Neuropharm, Teva, Sumitomo Dainippon, Allergan, Bausch Health, are heavily investing in R&D to develop new products and improve existing ones. This strategic emphasis on innovation is driving significant advancements in chemical manufacturing processes and the introduction of sustainable and eco-friendly products.Moreover, these established industry leaders are actively pursuing acquisitions of smaller companies to expand their regional presence and enhance their market share. These acquisitions not only help in diversifying their product portfolios but also provide access to new technologies and markets. This consolidation trend is a critical factor in the growth of the Second-Generation Antipsychotics, as it enables larger companies to streamline operations, reduce costs, and increase their competitive edge.
In addition to R&D and acquisitions, there is a notable shift towards green investments among key players in the Second-Generation Antipsychotics. Companies are increasingly committing resources to sustainable practices and the development of environmentally friendly products. This green investment is in response to growing consumer demand for sustainable solutions and stringent environmental regulations. By prioritizing sustainability, these companies are not only contributing to environmental protection but also positioning themselves as leaders in the green chemistry movement, thereby fueling market growth.
Key Players
The companies highlighted in this profile were selected based on insights from primary experts and an evaluation of their market penetration, product offerings, and geographical reach:- Johnson & Johnson
- Eli Lilly
- Otsuka
- AstraZeneca
- Pfizer
- GSK
- Lundbeck
- Sun Pharma
- Teva
- Novartis
- Allergan
- Merck
- Biogen
- Sanofi
- Takeda
- H. Lundbeck
- Neurocrine
- Vanda
- Neuropharm
- Teva
- Sumitomo Dainippon
- Allergan
- Bausch Health
Second-Generation Antipsychotics Market Segmentation by Players
www.htfmarketinsights.com
Second-Generation Antipsychotics Dynamics
Driving Factor
The Second-Generation Antipsychotics is propelled by several key drivers, including the demand from diverse industrial sectors such as automotive, construction, and pharmaceuticals. Technological advancements and continuous innovation in chemical processes enhance efficiency and open new market opportunities. Economic growth, particularly in emerging markets, along with rapid urbanization and population growth, increases the need for chemicals in infrastructure and consumer goods. Additionally, stricter environmental regulations and the push for sustainable products drive the development of green chemicals. Global trade, raw material availability, and investments in research and development further shape the industry's growth, while supportive government policies and evolving consumer trends also play crucial roles.
- Rising Mental Health Issues, Advances In CNS Drug Research, Better Patient Compliance, Government Support For Mental Health, Increasing Awareness, Expansion In Psychiatric Care
The Second-Generation Antipsychotics faces several challenges and restraining factors, including stringent environmental regulations that increase operational costs and complexity. Fluctuating raw material prices and availability can impact production expenses while growing health and safety concerns necessitate significant investments in compliance measures. Additionally, the push for sustainability requires costly reforms and green technologies. Economic uncertainty, supply chain disruptions, and rapid technological advancements further complicate market dynamics. Geopolitical instability and intellectual property risks also pose significant threats, while market saturation in mature regions pressures profit margins and limits growth opportunities.
- Side Effects (weight Gain, Diabetes), Regulatory Scrutiny, Stigma Around Mental Illness, High Development Cost, Competition With Traditional Antipsychotics, Patient Non-adherence
The Second-Generation Antipsychotics presents numerous opportunities for growth and innovation. Emerging trends in sustainability offer significant prospects for developing green and eco-friendly products, which are increasingly demanded by consumers and regulated by governments. Advancements in technology, such as digitalization and automation, provide opportunities for improving efficiency and reducing costs in chemical production. Expansion into emerging markets and developing regions presents a chance for companies to tap into new customer bases and increase their market share. Additionally, ongoing investments in research and development pave the way for innovations in specialty chemicals and advanced materials. Collaborations and partnerships within the industry can also drive growth by leveraging complementary strengths and accessing new technologies and markets.
- Pediatric And Adolescent Psychiatry Market, Telemedicine For Mental Health, Rural Mental Health Programs, Biosimilar Innovation, Cognitive Enhancement Therapies, Pharma Partnerships
Key trends in the Second-Generation Antipsychotics include a focus on sustainability and green chemistry, driven by environmental regulations and consumer demand. Digital transformation is enhancing efficiency through AI and automation, while advanced materials are being developed for various industries. The shift towards a circular economy promotes recycling and reuse, and personalized medicine is increasing demand for specialty chemicals. Investments in renewable energy create new opportunities, and emerging markets offer growth potential. Evolving regulations and consumer preferences for sustainable products are influencing innovation, and supply chain advancements are improving efficiency. These trends are reshaping the chemical industry and driving its growth.
- Long-acting injectables, Personalized treatment protocols, Digital health integration, Generic drug launches, Cross-border licensing, Value-based care models
Regulatory Framework
Several regulatory bodies oversee the chemical industry globally to ensure safety, environmental protection, and compliance with standards. Notable among these are the Environmental Protection Agency (EPA) in the United States, the European Chemicals Agency (ECHA) in the European Union, and the Occupational Safety and Health Administration (OSHA) in the United States. Other significant entities include the Health and Safety Executive (HSE) in the United Kingdom, the National Institute of Chemical Safety (NICS) in South Korea, and the Ministry of Environmental Protection (MEP) in China.Additionally, the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) in Australia, the Japan Chemical Industry Association (JCIA), the Canadian Environmental Protection Act (CEPA), and the Central Pollution Control Board (CPCB) in India play crucial roles. These organizations establish regulations, conduct inspections, and enforce compliance to ensure the safe production, handling, and disposal of chemicals.
Regional Insight
The North America leads the market share, largely due to rising consumption, a growing population, and strong economic momentum that boosts demand. In contrast, the Asia-Pacific is emerging as the fastest-growing area, driven by rapid infrastructure development, the expansion of industrial sectors, and heightened consumer demand, making it a critical factor for future market growth. The regions covered in the report are:Regions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
Dominating Region
North America
Market Segmentation
Segmentation by Type
- Atypical antipsychotics
- Injectable forms
- Oral tablets
Second-Generation Antipsychotics Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Treatment of schizophrenia
- Bipolar disorder
- Depression
- Anxiety
Second-Generation Antipsychotics Market Segmentation by Application
www.htfmarketinsights.com
Research Methodology
The research methodology involves several key steps to ensure comprehensive and accurate insights. First, the objectives of the research are clearly defined, focusing on aspects such as market size, growth trends, and competitive dynamics. Data collection is conducted through both primary and secondary methods. Primary research includes interviews with industry experts, surveys, and focus groups to gather first-hand information, while secondary research involves analyzing existing reports, government publications, and company filings.The collected data is then subjected to rigorous analysis, with quantitative methods used to evaluate market size and trends, and qualitative methods applied to understand industry dynamics and consumer behavior. Findings are compiled into a detailed report featuring key insights, data visualizations, and strategic recommendations. Validation is achieved through data verification and peer reviews to ensure accuracy.
Finally, the research concludes with actionable insights and recommendations, along with suggestions for future studies to address emerging trends and gaps. This methodology provides a structured approach to understanding the {keywords} and guiding strategic decisions.
Report Details
| Report Features | Details |
| Base Year | 2024 |
| Based Year Market Size (2024) | 4.5Billion |
| Historical Period | 2020 to 2024 |
| CAGR (2024 to 2032) | 8.00% |
| Forecast Period | 2025 to 2032 |
| Forecasted Period Market Size (2032) | 8.0Billion |
| Scope of the Report | Atypical antipsychotics, Injectable forms, Oral tablets, Treatment of schizophrenia, Bipolar disorder, Depression, Anxiety |
| Regions Covered | North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
| Companies Covered | Johnson & Johnson, Eli Lilly, Otsuka, AstraZeneca, Pfizer, GSK, Lundbeck, Sun Pharma, Teva, Novartis, Allergan, Merck, Biogen, Sanofi, Takeda, H. Lundbeck, Neurocrine, Vanda, Neuropharm, Teva, Sumitomo Dainippon, Allergan, Bausch Health |
| Customization Scope | 15% Free Customization |
| Delivery Format | PDF and Excel through Email |
Second-Generation Antipsychotics - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Second-Generation Antipsychotics Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Second-Generation Antipsychotics Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Second-Generation Antipsychotics Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising mental health issues, Advances in CNS drug research, Better patient compliance, Government support for mental health, Increasing awareness, Expansion in psychiatric care
-
3.2 Available Opportunities
- 3.2.1 Pediatric and adolescent psychiatry market, Telemedicine for mental health, Rural mental health programs, Biosimilar innovation, Cognitive enhancement therapies, Pharma partnerships
-
3.3 Influencing Trends
- 3.3.1 Long-acting injectables, Personalized treatment protocols, Digital health integration, Generic drug launches, Cross-border licensing, Value-based care models
-
3.4 Challenges
- 3.4.1 Side effects (weight gain, diabetes), Regulatory scrutiny, Stigma around mental illness, High development cost, Competition with traditional antipsychotics, Patient non-adherence
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Second-Generation Antipsychotics Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Second-Generation Antipsychotics Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Second-Generation Antipsychotics : Competition Benchmarking & Performance Evaluation
- 5.1 Global Second-Generation Antipsychotics Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Second-Generation Antipsychotics Revenue 2024
- 5.3 Global Second-Generation Antipsychotics Sales Volume by Manufacturers (2024)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Strategic Group Analysis
- 5.6 5C’s Analysis
Chapter 6: Global Second-Generation Antipsychotics Market: Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Overview
- 6.1.2 Johnson & Johnson Product/Service Portfolio & Specifications
- 6.1.3 Johnson & Johnson Key Financial Metrics
- 6.1.4 Johnson & Johnson SWOT Analysis
- 6.1.5 Johnson & Johnson Development Activities
- 6.2 Eli Lilly
- 6.3 Otsuka
- 6.4 AstraZeneca
- 6.5 Pfizer
- 6.6 GSK
- 6.7 Lundbeck
- 6.8 Sun Pharma
- 6.9 Teva
- 6.10 Novartis
- 6.11 Allergan
- 6.12 Merck
- 6.13 Biogen
- 6.14 Sanofi
- 6.15 Takeda
- 6.16 H. Lundbeck
- 6.17 Neurocrine
- 6.18 Vanda
- 6.19 Neuropharm
- 6.20 Teva
- 6.21 Sumitomo Dainippon
- 6.22 Allergan
- 6.23 Bausch Health
- 6.24 Sunovion
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Second-Generation Antipsychotics by Type & Application (2020-2032)
-
7.1 Global Second-Generation Antipsychotics Market Revenue Analysis (USD Million) by Type (2020-2024)
- 7.1.1 Atypical Antipsychotics
- 7.1.2 Injectable Forms
- 7.1.3 Oral Tablets
- 7.1.4 Combination Therapies
-
7.2 Global Second-Generation Antipsychotics Market Revenue Analysis (USD Million) by Application (2020-2024)
- 7.2.1 Treatment Of Schizophrenia
- 7.2.2 Bipolar Disorder
- 7.2.3 Depression
- 7.2.4 Anxiety
- 7.3 Global Second-Generation Antipsychotics Market Revenue Analysis (USD Million) by Type (2024-2032)
- 7.4 Global Second-Generation Antipsychotics Market Revenue Analysis (USD Million) by Application (2024-2032)
Chapter 8 : North America Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 8.1 North America Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 8.2.1 Atypical Antipsychotics
- 8.2.2 Injectable Forms
- 8.2.3 Oral Tablets
- 8.2.4 Combination Therapies
-
8.3 North America Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 8.3.1 Treatment Of Schizophrenia
- 8.3.2 Bipolar Disorder
- 8.3.3 Depression
- 8.3.4 Anxiety
- 8.4 North America Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 8.5 North America Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 8.6 North America Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 9.1 LATAM Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 9.2.1 Atypical Antipsychotics
- 9.2.2 Injectable Forms
- 9.2.3 Oral Tablets
- 9.2.4 Combination Therapies
-
9.3 LATAM Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 9.3.1 Treatment Of Schizophrenia
- 9.3.2 Bipolar Disorder
- 9.3.3 Depression
- 9.3.4 Anxiety
- 9.4 LATAM Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 9.5 LATAM Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 9.6 LATAM Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 10 : West Europe Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 10.1 West Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 10.2.1 Atypical Antipsychotics
- 10.2.2 Injectable Forms
- 10.2.3 Oral Tablets
- 10.2.4 Combination Therapies
-
10.3 West Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 10.3.1 Treatment Of Schizophrenia
- 10.3.2 Bipolar Disorder
- 10.3.3 Depression
- 10.3.4 Anxiety
- 10.4 West Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 10.5 West Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 10.6 West Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 11 : Central & Eastern Europe Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 11.2.1 Atypical Antipsychotics
- 11.2.2 Injectable Forms
- 11.2.3 Oral Tablets
- 11.2.4 Combination Therapies
-
11.3 Central & Eastern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 11.3.1 Treatment Of Schizophrenia
- 11.3.2 Bipolar Disorder
- 11.3.3 Depression
- 11.3.4 Anxiety
- 11.4 Central & Eastern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 11.5 Central & Eastern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 11.6 Central & Eastern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 12 : Northern Europe Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 12.2.1 Atypical Antipsychotics
- 12.2.2 Injectable Forms
- 12.2.3 Oral Tablets
- 12.2.4 Combination Therapies
-
12.3 Northern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 12.3.1 Treatment Of Schizophrenia
- 12.3.2 Bipolar Disorder
- 12.3.3 Depression
- 12.3.4 Anxiety
- 12.4 Northern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 12.5 Northern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 12.6 Northern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 13 : Southern Europe Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 13.2.1 Atypical Antipsychotics
- 13.2.2 Injectable Forms
- 13.2.3 Oral Tablets
- 13.2.4 Combination Therapies
-
13.3 Southern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 13.3.1 Treatment Of Schizophrenia
- 13.3.2 Bipolar Disorder
- 13.3.3 Depression
- 13.3.4 Anxiety
- 13.4 Southern Europe Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 13.5 Southern Europe Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 13.6 Southern Europe Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 14 : East Asia Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 14.1 East Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 14.2.1 Atypical Antipsychotics
- 14.2.2 Injectable Forms
- 14.2.3 Oral Tablets
- 14.2.4 Combination Therapies
-
14.3 East Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 14.3.1 Treatment Of Schizophrenia
- 14.3.2 Bipolar Disorder
- 14.3.3 Depression
- 14.3.4 Anxiety
- 14.4 East Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 14.5 East Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 14.6 East Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 15 : Southeast Asia Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 15.2.1 Atypical Antipsychotics
- 15.2.2 Injectable Forms
- 15.2.3 Oral Tablets
- 15.2.4 Combination Therapies
-
15.3 Southeast Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 15.3.1 Treatment Of Schizophrenia
- 15.3.2 Bipolar Disorder
- 15.3.3 Depression
- 15.3.4 Anxiety
- 15.4 Southeast Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 15.5 Southeast Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 15.6 Southeast Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 16 : South Asia Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 16.1 South Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 16.2.1 Atypical Antipsychotics
- 16.2.2 Injectable Forms
- 16.2.3 Oral Tablets
- 16.2.4 Combination Therapies
-
16.3 South Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 16.3.1 Treatment Of Schizophrenia
- 16.3.2 Bipolar Disorder
- 16.3.3 Depression
- 16.3.4 Anxiety
- 16.4 South Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 16.5 South Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 16.6 South Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 17 : Central Asia Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 17.1 Central Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 17.2.1 Atypical Antipsychotics
- 17.2.2 Injectable Forms
- 17.2.3 Oral Tablets
- 17.2.4 Combination Therapies
-
17.3 Central Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 17.3.1 Treatment Of Schizophrenia
- 17.3.2 Bipolar Disorder
- 17.3.3 Depression
- 17.3.4 Anxiety
- 17.4 Central Asia Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 17.5 Central Asia Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 17.6 Central Asia Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 18 : Oceania Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 18.1 Oceania Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 18.2.1 Atypical Antipsychotics
- 18.2.2 Injectable Forms
- 18.2.3 Oral Tablets
- 18.2.4 Combination Therapies
-
18.3 Oceania Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 18.3.1 Treatment Of Schizophrenia
- 18.3.2 Bipolar Disorder
- 18.3.3 Depression
- 18.3.4 Anxiety
- 18.4 Oceania Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 18.5 Oceania Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 18.6 Oceania Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 19 : MEA Second-Generation Antipsychotics Market Breakdown by Country, Type & Application
- 19.1 MEA Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 19.2.1 Atypical Antipsychotics
- 19.2.2 Injectable Forms
- 19.2.3 Oral Tablets
- 19.2.4 Combination Therapies
-
19.3 MEA Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 19.3.1 Treatment Of Schizophrenia
- 19.3.2 Bipolar Disorder
- 19.3.3 Depression
- 19.3.4 Anxiety
- 19.4 MEA Second-Generation Antipsychotics Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 19.5 MEA Second-Generation Antipsychotics Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 19.6 MEA Second-Generation Antipsychotics Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Second-Generation Antipsychotics Market is growing at a steady pace over the last few years and is expected to grow at a CAGR of 8.00% from 2024 to 2032 to reach a market size of 8.00% 8.0 billion
According to the report,the Second-Generation Antipsychotics Industry size is projected to reach 8.0 billion, exhibiting a CAGR of 8.00% by 2032.
Some of the prominent trends that are influencing and driving the growth of Global Second-Generation Antipsychotics Market are Long-acting Injectables, Personalized Treatment Protocols, Digital Health Integration, Generic Drug Launches, Cross-border Licensing, Value-based Care Models
The leaders in the Global Second-Generation Antipsychotics Market such as Johnson & Johnson, Eli Lilly, Otsuka, AstraZeneca, Pfizer, GSK, Lundbeck, Sun Pharma, Teva, Novartis, Allergan, Merck, Biogen, Sanofi, Takeda, H. Lundbeck, Neurocrine, Vanda, Neuropharm, Teva, Sumitomo Dainippon, Allergan, Bausch Health, Sunovion are targeting innovative and differentiated growth drivers some of them are Rising Mental Health Issues, Advances In CNS Drug Research, Better Patient Compliance, Government Support For Mental Health, Increasing Awareness, Expansion In Psychiatric Care
Business transformation in Second-Generation Antipsychotics Market has taken hold due to the confluence of several important triggers, some of them are Side Effects (weight Gain, Diabetes), Regulatory Scrutiny, Stigma Around Mental Illness, High Development Cost, Competition With Traditional Antipsychotics, Patient Non-adherence.
Some of the opportunities that Analyst at HTF MI have identified in Second-Generation Antipsychotics Market are:
- Pediatric And Adolescent Psychiatry Market, Telemedicine For Mental Health, Rural Mental Health Programs, Biosimilar Innovation, Cognitive Enhancement Therapies, Pharma Partnerships
Johnson & Johnson, Eli Lilly, Otsuka, AstraZeneca, Pfizer, GSK, Lundbeck, Sun Pharma, Teva, Novartis, Allergan, Merck, Biogen, Sanofi, Takeda, H. Lundbeck, Neurocrine, Vanda, Neuropharm, Teva, Sumitomo Dainippon, Allergan, Bausch Health, Sunovion etc are the main players listed in the Global Second-Generation Antipsychotics Market Study.
The Global Second-Generation Antipsychotics Market Study is Broken down by applications such as Treatment of schizophrenia, Bipolar disorder, Depression, Anxiety.
The Global Second-Generation Antipsychotics Market Study is segmented by Atypical antipsychotics, Injectable forms, Oral tablets, Combination therapies.
The Global Second-Generation Antipsychotics Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - Base year: 2024. Forecast period**: 2025 to 2032 [** unless otherwise stated]
The Second-Generation Antipsychotics (SGAs) Market comprises medications such as risperidone, olanzapine, quetiapine, and aripiprazole, used primarily to treat schizophrenia, bipolar disorder, and other psychotic conditions. These drugs act on dopamine and serotonin receptors, offering improved efficacy and fewer extrapyramidal side effects compared to first-generation antipsychotics. The market is driven by rising mental health awareness, increasing prevalence of psychiatric disorders, and expanding indications. Major pharmaceutical companies include Johnson & Johnson, Lilly, and Otsuka. Challenges involve managing metabolic side effects like weight gain and diabetes. The industry is focused on developing novel formulations, long-acting injectables, and personalized therapies. Regulatory approval processes, patent expirations, and generic entries influence market dynamics. Overall, the market aims to improve patient compliance, reduce side effects, and enhance therapeutic outcomes for mental health disorders worldwide.
